Prime.io - a london based cell line engineering service CRO company appoints Sir Tony Kouzarides to support long-term strategy for its Next Generation Cell Line Engineering Services.

Tony is a highly cited academic and entrepreneur who co-founded both the Milner Therapeutics Institute and Abcam (NASDAQ: ABCM). As scientific advisor, he will help guide prime.io's scientific strategy and explore new opportunities to raise awareness of the Company’s mission to edit genes and accelerate drug discovery.

Prime.io is a gene editing contract research organization (CRO) that uses AI-designed gene editing technology and automation to edit genes and accelerate drug discovery. The company is backed by a U.S.-based venture capital firm 50Y as well as Sir Tony Kouzarides.

​Cell line engineering services are available in the market but are far from reaching their full potential. Speed, quality, and scalability remain three key challenges facing the drug discovery industry when working with current endogenous gene editing service providers.

​The Prime.io team brings over 50 years of combined gene editing experience. Together with a proprietary AI-powered genome editor and automated platform, this enables drug discovery scientists to obtain high-quality endogenous gene-edited clones faster and at scale. This allows drug discovery companies to generate downstream functional cellular validation data more efficiently and make critical decisions faster and with greater confidence.

​Prime.io was founded in 2025 by Dr. Rex Li, CEO. The company is based at the London BioScience Innovation Centre (LBIC), 2 Royal College Street, London NW1 0NH.